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ABSTRACT 
CD1a is a lipid-presenting molecule abundantly expressed on Langerhans cells. However, the in 
vivo role of CD1a remains unclear, principally because CD1a is lacking in mice. Using CD1a-
transgenic mice, we show that urushiol from poison ivy triggers CD1a-dependent skin 
inflammation, driven by CD4 T cells producing IL-17 and IL-22. Notably, human subjects with 
poison ivy dermatitis showed a similar cytokine signature following CD1a-mediated urushiol 
recognition. Among different urushiol congeners, we identified diunsaturated pentadecylcatechol 
(C15:2) as the dominant antigen for CD1a-restricted T cells. We determined the crystal structure 
of the CD1a-urushiol (C15:2) complex, demonstrating the molecular basis of urushiol interaction 
with the antigen-binding cleft of CD1a. In a mouse model and psoriasis patients, CD1a amplified 
inflammatory responses mediated by Th17 cells reactive with self lipid antigens. Remarkably, 
treatment with blocking antibodies against CD1a alleviated skin inflammation. Thus, we propose 
CD1a as a potential target for future therapeutic strategies against inflammatory skin diseases.  
The family of CD1 molecules consists of group 1 CD1 (CD1a, b, c, and e) and group 2 CD1 
(CD1d) proteins1. In contrast to MHC proteins that present peptides, CD1 molecules present 
lipid antigens to T lymphocytes1-2. For example, the CD1d molecule presents α-anomeric 
glycosphingolipids to invariant NKT cells3, whereas CD1a-c molecules are mainly described to 
present lipids and lipopeptides from mycobacteria to a diverse T cell repertoire4. Notably, CD1a 
can display a broad spectrum of exogenous lipid antigens derived from pollen5 or bacteria6-8. In 
addition, CD1a also presents self lipid antigens from host origin9-15, such as triacylglycerol, 
squalene, wax ester, and fatty acid, which are enriched in the skin epidermis9. 
The abundant expression of CD1a hallmarks Langerhans cells in the skin. Langerhans cells 
originate from yolk-sac-derived fetal liver progenitors16,17, require IL-34 for development18, and 
constitute the principal dendritic cell (DC) subset in the epidermis19,20. Additionally, the dermis 
harbors dermal as well as langerin-positive DCs. The three DC types in the skin fulfill different 
functions in antigen presentation: Langerin-positive dermal DCs are important for cross-priming 
of CD8 T cells, whereas Langerhans cells preferably induce Th17 cells21,22. 
The intricate immune system of the skin is critically involved in responses to extrinsic insults 
like allergens23, as well as in autoimmune diseases, such as psoriasis24,25. Contact dermatitis is a 
common skin disease caused by exposure to small organic or inorganic molecules23. During the 
sensitization phase, allergen-specific T lymphocytes are generated that mediate skin 
inflammation upon challenge with the same antigen23. The sap compound urushiol of the plant 
poison ivy can trigger severe inflammation, and urushiol-specific T cells have been implicated in 
this process in the human system26-28. Psoriasis is a chronically relapsing, T cell-mediated 
inflammatory skin disease with a prevalence of 2-3% worldwide24,25. The disease is 
characterized by epidermal thickening (acanthosis), which leads to itchy and scaling plaques on 
the macroscopic level24,25. Importantly, it is well known that the cytokines IL-17 and IL-22 are 
crucial for the development of psoriasis25. Although psoriasis is considered an autoimmune 
disease, the nature of the antigens recognized remain elusive25.  
Considering that Langerhans cells predominantly express CD1a and reside in the epidermis that 
is readily accessible to foreign as well as self lipid antigens, Langerhans cells and CD1a-
restricted T cells are prime candidates for regulating skin immunity. However, since CD1a is 
expressed in humans but lacking in mice1, the in vivo functions of CD1a on Langerhans have not 
been addressed and remain unclear. 
Here, we show the vital importance of Langerhans cells expressing CD1a in skin inflammation 
in vivo. To demonstrate a role of CD1a on Langerhans cells in the induction of inflammatory 
skin diseases, we used human CD1a-transgenic mice and found that CD1a drives pathogenesis of 
poison ivy dermatitis and psoriasis. Furthermore, we showed that CD1a-mediated skin 
inflammation is abrogated by CD1a blocking antibodies, highlighting CD1a as a novel target for 
treatment of inflammatory skin diseases.  
RESULTS 
CD1a promotes Th17-mediated skin inflammation in response to poison ivy  
Based on its lipophilic nature and the chemical structure of pentadecylcatechol, we hypothesized 
that urushiol could represent a ligand displayed by the lipid-presenting molecule CD1a to cause 
inflammation. To this end, we sensitized and challenged CD1a-transgenic (CD1aTg) or wild-
type (WT) mice with urushiol applied to the skin (30 µl of 20 mg/ml for sensitization; 10 µl of 5 
mg/ml for challenge). Ear thickness as a first indicator of inflammation was strikingly increased 
in the presence of CD1a (Fig. 1a). Histological analysis revealed a pronounced cellular infiltrate 
especially in the dermis of urushiol-treated CD1aTg animals (Fig. 1b). Subsequently, we 
analyzed the skin-infiltrating cells by flow cytometry and found a significant increase in 
inflammatory granulocytes and macrophages in CD1aTg mice (Fig. 1c,d). Dermal T 
lymphocytes bearing a γδ T cell receptor (TCR) expanded to the same extent in both mouse 
strains (Fig. 1e,f). By contrast, the presence of CD1a promoted the specific amplification of CD4 
αβ T cells, whereas the participation of CD8 T cells proved to be negligible (Fig. 1e,f). 
Investigating the functional cytokine responses of these lymphocytes, we found that the 
abundance of CD4 T cells producing IL-17 and IL-22 (Th17 cells) was drastically increased in 
the CD1aTg mouse model (Fig. 1g,h). Thus, CD1a promotes Th17-mediated skin inflammation 
in response to poison ivy. Next, we investigated whether our findings in the mouse model were 
relevant in humans. For this purpose, we tested memory T cells from the blood of human 
subjects who experienced moderate-to-severe poison ivy rash in the past six months. CD1a-
transfectant antigen-presenting cells or parental control cells were pulsed with urushiol or 
vehicle, prior to coculture with T lymphocytes from poison ivy or healthy donors. Subsequent 
analysis of T cell activation revealed increased IL-17- and IL-22 production of T cells from 
poison ivy donors that specifically responded to urushiol in a CD1a-dependent manner (Fig. 
2a,b). Thus, in the context of our data in the CD1a-transgenic system, human subjects with 
poison ivy dermatitis showed a similar inflammatory cytokine signature following CD1a-
mediated urushiol recognition. 
Adaptive immunity to poison ivy is distinct from a classical hapten response 
Next, we determined whether the immune response to urushiol was based on adaptive immunity, 
or innate mechanisms locally at work in the skin. In the absence of initial sensitization, CD1aTg 
mice that were only challenged with urushiol failed to develop increased skin inflammation, as 
indicated by skin infiltration and IL-17-producing CD4 T cells (Fig 3a,b). Although urushiol 
showed a direct impact on innate inflammation, upregulation of inflammatory mediators, such as 
IL-1β and TNF-α, was comparable between CD1aTg and wild-type mice (Supplementary Fig. 
1). Therefore, CD1a-dependent immunity to urushiol involves antigen-specific T cell priming. 
To exclude a generally increased susceptibility of CD1aTg mice to antigenic stimulation, we 
tested the immune response to the classical hapten dinitrofluorobenzene (DNFB)23. Surprisingly, 
ear swelling was reduced in the CD1aTg mouse model when compared to wild-type 
(Supplementary Fig. 2a). In addition to reduced influx of inflammatory granulocytes, CD1aTg 
mice generated drastically less CD8 T cells in response to DNFB and accordingly showed 
reduced IFN-γ production (Supplementary Fig. 2b,c). Thus, the CD1aTg mice do not have a 
generally increased susceptibility to stimulation with hapten. 
CD1a on Langerhans cells is important for generation of Th17 cells and dermatitis 
Using confocal microscopy of epidermal sheets, we demonstrate the Langerhans cell network in 
the epidermis as well as their exclusive CD1a expression in the CD1aTg mouse model (Fig. 4a). 
Moreover, we analyzed all skin DCs by flow cytometry and found the CD1a-positive population 
to super-impose with langerin-expressing Langerhans cells (Fig. 4b). Subsequently, we 
monitored CD1a expression on skin DCs during the immune response to urushiol. In vehicle-
treated control skin, the composition of skin DCs proved to be comparable between CD1aTg and 
wild-type mice, indicating normal homeostasis (Fig. 4c). In the inflamed ear skin, we observed a 
massive influx of inflammatory, CD1a-negative DCs. By contrast, epidermal Langerhans cells 
were the main population specifically expressing CD1a in poison ivy dermatitis (Fig. 4c). Based 
on this exclusive expression pattern, we next aimed at inhibiting CD1a function on Langerhans 
cells. For this purpose, we treated mice during the sensitization phase with CD1a blocking 
antibodies. Strikingly, anti-CD1a treatment reduced ear swelling in CD1aTg animals to wild-
type levels as compared to administration of isotype control antibodies (Fig. 4d). Accordingly, 
infiltration of inflammatory granulocytes and IL-17-producing CD4 T cells was equally 
abrogated by anti-CD1a treatment (Fig. 4e,f). Of note, antibody application had no depletional 
effect but rather blocked CD1a function on the surface of Langerhans cells. In this context, we 
found downregulation of CD1a on skin Langerhans cells upon antibody treatment, although 
diminishment of CD1a appeared incomplete possibly due to limited accessibility of the 
epidermis for systemically administered antibodies (Fig. 4g). However, in skin-draining lymph 
nodes, anti-CD1a treatment led to full downregulation of CD1a on migrating Langerhans cells 
(Fig. 4g). Taken together, CD1a-expressing Langerhans cells are essential for generation of 
Th17 cells and skin inflammation. 
Urushiol (C15:2) is the dominant antigen for CD1a-restricted T cells  
Since poison ivy induced strong CD1a-mediated inflammation, we next investigated whether 
urushiol is a bona fide antigen presented by CD1a. For this purpose, we incubated plate-bound 
recombinant human CD1a molecules with urushiol, prior to culture with CD4 T cells isolated 
from urushiol-immunized mice. In sharp contrast to lymphocytes from wild-type mice, only CD4 
T cells isolated from CD1aTg animals produced IL-17 in response to urushiol-loaded CD1a 
molecules (Fig. 5a). This system is free of antigen-presenting cells and thus demonstrates the 
direct presentation of urushiol by CD1a. Since natural urushiol contains a mixture of different 
pentadecylcatechols, we subsequently determined which congener of poison ivy was responsible 
for its antigenic properties. Using the same recombinant CD1a system, we found that 
pentadecylcatechol with two unsaturations (C15:2) is the dominant immunogen for CD1a-
mediated T cell activation (Fig. 5b). We also showed that C15:2 mediated the observed effects 
of increased skin inflammation in CD1aTg mice (Fig. 5c). In order to mimic urushiol 
presentation in its natural habitat, we isolated Langerhans cells from ear skin of immunized 
CD1aTg animals, prior to pulsing with C15:2 and coculture with CD4 T cells from draining 
lymph nodes. Langerhans cells triggered a strong Th17 cell response upon C15:2 presentation in 
a strictly CD1a-specific manner, because anti-CD1a fully abolished T cell activation (Fig. 5d). 
Of note, a substantial degree of autoreactive, CD1a-restricted T cell stimulation could be 
observed with unpulsed Langerhans cells (Fig. 5d). A classical feature of adaptive immunity is 
the clonal expansion of antigen-specific T cells, characterized by a certain TCR usage of 
amplified cells. Therefore, we investigated the TCR repertoire of the immune response to 
urushiol. Notably, T cells exhibited a significant increase in Vβ2 and Vβ4 TCR usage in 
inflamed skin of CD1aTg mice, suggesting clonal expansion under antigenic selection pressure 
(Supplementary Fig. 3a). The Vβ2+ and Vβ4+ T cell clones produced higher amounts of IL-17 
in CD1aTg animals compared to wild-type mice (Supplementary Fig. 3b). Moreover, 
amplification of Vβ2+ and Vβ4+ T cells was significantly hampered when CD1a function was 
blocked by antibody treatment (Supplementary Fig. 3c). These changes in TCR repertoire were 
specific for T cells in skin inflammation, because normal control skin showed no difference in 
TCR usage between wild-type and CD1aTg mice (Supplementary Fig. 3d). Additionally, the 
CD1aTg mouse model revealed no alterations of the TCR repertoire in the thymus, excluding 
differential thymic selection (Supplementary Fig. 3e). Altogether, our results on functional 
presentation and TCR repertoire suggest that urushiol is an antigen for CD1a-restricted T cells.  
Crystal structure of the CD1a-urushiol (C15:2) complex 
Therefore, we aimed to obtain molecular insight into the mechanism of CD1a presenting 
urushiol. To establish this, we recombinantly expressed the CD1a molecule in mammalian cells 
and in vitro loaded the urushiol ligand (C15:2). As CD1a expressed in mammalian cells 
comprises a heterogeneous array of self lipid ligands within its antigen-binding cleft, the 
endogenous lipids were initially displaced by the ganglioside GD3. Subsequently, GD3 bound to 
CD1a was specifically displaced by urushiol, with the CD1a-urushiol complex being purified 
from CD1a-GD3 via anion-exchange chromatography. Next, we crystallized and determined the 
structure of the CD1a-urushiol binary complex to 1.9Å resolution (Fig. 6a and Supplementary 
Table 1). Unbiased electron density was visible for the urushiol ligand, with the ligand clearly 
being non-covalently bound within the CD1a antigen-binding cleft (Supplementary Fig. 4). 
Mass spectrometry analysis confirmed the presence of urushiol (m/z 317.24) both in the purified 
recombinant CD1a sample loaded with urushiol and in crystals of the CD1a-urushiol binary 
complex (Fig. 6b,c). Accordingly, CD1a directly presents urushiol. 
The antigen-binding cleft of CD1a comprises the A’- and F’-pockets, in which the A’-pocket is 
considered to function as a molecular ruler, favoring acyl chains between C18-20 in length
14. For 
example, in the structure of the CD1a-lysophosphatidylcholine complex, the acyl chain winds 
round the A’-pocket while the polar headgroup is positioned at the junction of A’- and F’-
portals15. As anticipated, the urushiol antigen is positioned deep in the CD1a binding cleft, 
spanning from the A’- to the F’-pocket (Supplementary Fig. 4a). Surprisingly however, the 
catechol headgroup and acyl chain were positioned towards the A’- and F-pockets, respectively, 
in the reverse direction to what may have been anticipated based on previous CD1a-antigen 
structures (Fig. 6a, right panel)4. Here, the urushiol antigen mainly interacted via van der Waals 
contacts with residues of the α1-helix of CD1a (Fig. 6a and Supplementary Table 2). The 
aromatic catechol headgroup of the antigen was positioned in the A’-pocket and stacked against 
Phe70, while the 3’-hydroxyl formed a hydrogen bond with the main chain carbonyl of Leu66. 
The C15:2 aliphatic tail of urushiol sat over the hydrophobic platform formed by Val12, Trp14, 
Val98, and Leu116 (Fig. 6a). 80% of the urushiol molecule is buried within the CD1a cleft 
(Buried Surface Area of ~495 Å2). Thus, CD1a presents the urushiol antigen with 20% of its 
molecular surface potentially exposed at the F’-portal for direct TCR contact (Supplementary 
Fig. 4b).  
CD1a facilitates psoriatic skin inflammation dominated by Th17 cells 
Based on the substantial IL-17 production by CD1a-autoreactive T cells (Fig. 5d) and the 
prominent function of IL-17 in psoriasis24,25, we hypothesized that CD1a might play an important 
role in psoriatic inflammation. Therefore, we investigated CD1aTg mice in a well-established 
model for psoriasiform inflammation, using skin administration of the small molecule compound 
imiquimod29. Histological analysis revealed strong cellular infiltration of the skin and dramatic 
epidermal hyperplasia in CD1aTg mice when compared to controls (Fig. 7a). Histopathology 
was reflected in the macroscopic, psoriasis-like aspect of ear skin that exhibited swelling, 
reddening, and scaling (Fig. 7a,b). Next, we aimed at therapy of psoriasiform inflammation 
using CD1a blocking antibodies. Strikingly, anti-CD1a treatment significantly reduced skin 
inflammation in CD1aTg animals (Fig. 7c). This therapeutic effect was mirrored by reduction of 
inflammatory granulocytes and CD4 T cells that produced IL-17A, IL-17F, and IL-22 (Fig. 
7d,e). Taking into account that we did not challenge CD1aTg mice with exogenous lipids in this 
psoriasis model, we hypothesized that during the inflammatory process, self lipid antigens are 
released to facilitate CD1a-mediated T cell responses and skin inflammation. To this end, we 
isolated T cells from skin-draining lymph nodes of imiquimod-treated mice, prior to incubation 
with plate-bound CD1a molecules loaded with self lipids that have been previously reported as 
skin antigens9. T cells from CD1aTg mice specifically responded to CD1a-restricted self lipid 
presentation, with pronounced recognition of fatty acid and triacylglycerol (Fig. 7f). Of note, we 
could not detect any meaningful production of IL-17 in untreated controls, underscoring that in 
the absence of inflammation, there is a complete lack of self lipid antigen presentation and 
recognition (Fig. 7f). Ultimately, we wanted to translate our findings in the psoriasis-like model 
to the human system. For this purpose, we studied a cohort of patients with moderate-to-severe 
plaque psoriasis compared to healthy donors, measuring CD1a-restricted T cell activation. 
Accordingly, memory T cells from the blood of psoriasis patients or healthy donors were 
stimulated with autologous monocyte-derived DCs in the presence or absence of anti-CD1a, 
prior to measurement of cytokine responses. Notably, we observed an increase in protein 
production of IL-17 and IL-22 in T cells from psoriasis patients when compared to healthy 
controls (Fig. 7g). Moreover, the inflammatory cytokine response from patients was significantly 
blocked by anti-CD1a treatment (Fig. 7g). Taken mouse model for psoriasis and human studies 
together, we present strong evidence that CD1a drives psoriatic skin inflammation and that 
targeting CD1a can abrogate inflammatory skin disease.  
DISCUSSION 
Using the CD1a-transgenic model, our studies demonstrate a vital role for CD1a in skin 
inflammation in vivo. Since wild-type mice lack CD1a expression, previous reports investigating 
Langerhans cell functions in the murine system neglect the integral role of CD1a. Therefore, our 
new model is able to demonstrate the entire spectrum of Langerhans cell abilities, including 
CD1a as their prominent hallmark molecule. We show that poison ivy-induced skin 
inflammation is dominated by CD1a-dependent Th17 cells. Using wild-type mice in the absence 
of CD1a, previous work suggested CD8 T cells and IFN-γ to respond to urushiol30. However, the 
magnitude of inflammation appeared to be relatively mild30, which is in agreement with our 
observations in control animals. In sharp contrast, the response to poison ivy is much stronger in 
humans, including skin reddening, blistering, and vigorous itch – a severity well reflected in the 
CD1a-transgenic mouse model. Urushiol is commonly considered as pro-hapten, whose catechol 
group is oxidized to a quinone that subsequently reacts with endogenous proteins to form an 
immunogen23. Normally, contact hypersensitivity to haptens is driven by CD8 T cells producing 
IFN-γ, as seen in response to DNFB and drug hypersensitivities23,31. By contrast, we demonstrate 
urushiol-specific, CD1a-restricted activation of CD4 T cells that secrete IL-17. Moreover, 
immune stimulation by DNFB was suppressed in CD1aTg mice, indicating that CD1a does not 
favor hapten responses.  
Based on presentation experiments using recombinant CD1a or Langerhans cells, and our 
structural studies on the CD1a-urushiol complex, we demonstrate that urushiol (C15:2) is a 
veritable antigen for CD1a-restricted T cells. While the overall structural features of the CD1a 
binding cleft were generally conserved upon urushiol binding by comparison to the previous 
CD1a-antigen complexes15, two CD1a residues deep within the A’-pocket underwent structural 
rearrangements in order to accommodate the urushiol antigen in the binding groove. Namely, 
Phe70 and Trp14 swung away to provide space for the catechol headgroup and the C15-tail of 
urushiol, respectively (Fig. 6a). These conformational changes had the knock-on effect of 
altering the conformation of the CD1a antigen-binding cleft (root mean square deviation of 0.6 
Å), in particular residues 146-150 (r.m.s.d. of 1.3 Å), which subsequently impacted on the 
conformation of Arg73, Arg76, and Glu154 (Fig. 6a), a constellation of residues known to 
impact on the autoreactivity of a CD1a-restricted TCR15. Thus, a region of the urushiol antigen is 
accessible for direct TCR contact within the CD1a groove (Supplementary Fig. 4b), and 
moreover, the accommodation of urushiol leads to conformational changes within CD1a that 
could also directly impact on TCR recognition. However, future studies will be required to show 
the ternary structure of CD1a-urushiol-TCR. 
Furthermore, we demonstrated that CD1a on Langerhans cells controls inflammation in 
psoriasis, exploring a psoriasis-like mouse model as well as patients. Considering our findings on 
presentation of fatty acid and triacylglycerol, we propose that self lipids could represent 
dominant antigens in psoriasis when displayed by CD1a. A recent study revealed that self lipids 
fitting into the CD1a binding groove can change the conformation of CD1a to be recognized by 
specific TCRs, in a mechanism of permissive autoreactivity15. Integrating follow-up human 
studies using patient samples, the concept of self lipids might provide important answers to the 
long quest for antigens so far unknown in psoriasis. The skin harbors a multitude of immune 
cells involved in the response to challenges. Dermal γδ T cells produce IL-17 and have been 
associated with psoriasis32,33. We observed a comparable increase of dermal γδ T cells in 
CD1aTg or wild-type mice in response to urushiol or imiquimod. By contrast, amplification of 
IL-17-producing αβ T cells was specific for the CD1aTg model, thus explaining the predominant 
impact of CD1a-dependent Th17 cells on skin inflammation. Yet, both T cell populations can 
complement each other, with γδ T cells responding early and in an innate fashion to cytokines 
such as IL-23, and CD1a-restricted Th17 cells acting at a later stage in a lipid antigen-specific 
manner. In psoriasis patients, we found a particular increase in inflammatory IL-17 and IL-22 
production upon recognition of CD1a. Finally, our results demonstrate that blocking CD1a in 
vivo using antibody treatment is able to substantially reduce skin inflammation. Thus, we 
propose targeting of CD1a to pave the way for future CD1a-based therapies against 
inflammatory skin diseases. 
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METHODS 
Reagents. RPMI medium 1640, propidium iodide (PI), ethylenediaminetetraacetic acid (EDTA), 
β-mercaptoethanol, penicillin and streptomycin, sodium pyruvate, and L-glutamine were 
purchased from Life Technologies. Fetal bovine serum (FBS), bovine serum albumin (BSA), and 
phosphate-buffered saline (PBS) were from Sigma-Aldrich. RPMI medium 1640 was 
supplemented with 10% FBS, penicillin and streptomycin (10 U/ml), sodium pyruvate (1 mM), 
L-glutamine (2 mM), β-mercaptoethanol (50 µM), and HEPES (100 mM). Purified natural 
urushiol was a generous gift from Alfred Del Grosso at the Food and Drug Administration 
(FDA). Synthetic urushiols C15:1, C15:2, and C15:3 were purchased from Phytolab (Germany). 
Synthetic urushiol C15:0 was obtained from ChromaDex. Palmitoleic acid, squalene, and 
glyceryl tripalmitoleate were purchased from Sigma-Aldrich. Oleyl palmitoleate and oleyl oleate 
were from Nu-Chek.  
 
Antibodies. For flow cytometry, cells were stained with following antibodies: anti-CD3ε (145-
2C11), anti-CD8α (53-6.7), anti-CD4 (GK1.5), anti-CD45.2 (104), anti-IFN-γ (XMG1.2), anti-
CD1a (HI149), anti-IL-17F (9D3.1C8), anti-IL-22 (Poly5164), anti-γδTCR (GL3), anti-CD11b 
(M170), anti-Gr-1 (RB6-8C5), anti-F4/80 (BM8), anti-CD11c (N418), and anti-CD11a (M17/4) 
were purchased from BioLegend. Anti-IL-17A (ebio17B7), anti-CD207 (eBioL31), anti-CD103 
(2E7), anti-RORγt (B2D), and anti-MHC class II (M5/114.15.2) were from eBioscience. Anti-
CD1a antibody (10H3) for blocking was kindly provided by Michael Brenner at Brigham and 
Women's Hospital. Anti-CD16/CD32 (2.4G2) was acquired from Bio-XCell. Secondary 
antibodies anti-mouse IgG and anti-rat IgG were from Life Technologies. To study the repertoire 
of Vβ TCRs, the Mouse Vβ TCR Screening Panel (BD Pharmingen) was used.  
 Mice and models of skin inflammation. Human CD1a-transgenic mice were generated as 
previously reported34. C57BL/6 and OT-II transgenic mice were purchased from The Jackson 
Laboratory. Sex- and age-matched animals between 8 and 12 weeks of age were used for 
experiments. Preliminary experiments were performed to determine proper sample size. All 
animal experiments were approved by the Institutional Animal Care and Use Committee 
(IACUC) of Harvard Medical School. For triggering skin inflammation, mice were sensitized on 
the shaved abdomen with 30 µl of 20 mg/ml urushiol, or 0.5% DNFB (Sigma) dissolved in 
acetone (Sigma). Five days after sensitization, mice were challenged on dorsal and ventral side 
of the ear with 10 µl of 5 mg/ml urushiol or 0.2% DNFB. To induce psoriatic skin inflammation, 
5% imiquimod cream (Glenmark) was topically applied on dorsal and ventral sides of ears for 6-
7 consecutive days as previously described35. Ear thickness was measured before and after 
treatment using a micrometer (Swiss Precision Instruments). To block CD1a-dependent 
responses, mice were injected with 100 µg of anti-CD1a or isotype control antibody at -3, -1, +1, 
+3, +5 days before and after treatment.   
 
Mouse tissue preparation. Ears were excised, split into two halves at an angle parallel to the 
cartilage, and further cut into small pieces. Tissue samples were digested in RPMI containing 0.1 
mg/ml Liberase TM (Roche Diagnostic Corp.), 0.1 mg/ml DNase I (Roche Diagnostic Corp.), 
and 20 µM HEPES (Life Technologies) for 2 hours at 37°C with shaking (140 rpm). Digested 
samples were minced through a metal mesh, and filtered with a 70 µm nylon strainer (BD 
Biosciences). Auricular lymph nodes and thymi were harvested and minced through a metal 
mesh to obtain single cell suspensions. To isolate CD4 T cells, cell suspensions were incubated 
with anti-CD16/CD32 for 10 minutes on ice, and CD4-positive cells were selected using CD4 
magnetic beads and MACS columns (Miltenyi Biotec) according to manufacturer’s protocol.  
 
Langerhans cell isolation. Langerhans cells (LCs) from ear skin were isolated as previously 
described36. Briefly, ears were split into dorsal and ventral halves, and incubated in 0.8% trypsin 
solution (Sigma-Aldrich) for 25-45 minutes at 37°C. Epidermal layers were peeled off from the 
dermis and transferred into complete RPMI medium, followed by stirring for 40 minutes at 37°C 
in a water bath incubator (Labline Instruments). Cell suspensions were passed through 70 µm 
nylon strainers. To remove dead cells, a gradient centrifugation with Percoll (GE Healthcare) 
was performed. Cells were stained with anti-CD11c magnetic beads, and CD11c-positive cells 
were sorted by MACS columns. Approximately 70% of isolated cells were CD1a+MHC class II+ 
LCs.  
 
T cell assay with LCs. LCs were pulsed with 5 µg/ml urushiol or vehicle in complete media for 
2 hours, and subsequently co-cultured with T cells at a ratio of 1:5 in 96-well round-bottom 
plates. To block CD1a-dependent responses, LCs were incubated with 10 µg/ml anti-CD1a 
(10H3) or isotype control antibody for 2 hours, prior to the addition of T cells. After 3 days, 
culture supernatants were harvested to perform ELISA for IL-17A and IFN-γ.  
 
T cell experiments with plate-bound recombinant CD1a. Biotinylated CD1a monomers 
paired with β2-microglobulin (β2M) were provided by the NIH Tetramer Facility. CD1a-coated 
plates and lipid antigens were prepared as described previously9. Briefly, streptavidin-coated 
plates (Thermo Scientific) were incubated with biotinylated human CD1a-β2M monomers (1 
µg/well) and anti-CD11a (0.25 µg/ml) in PBS for 18 hours at room temperature. After washing 
with PBS, the plates were incubated with citrate buffer (pH 3.4) for 20 minutes, repeated twice 
with three washing steps in between. Lipid antigens were dissolved in PBS containing 0.05% 
Tween 20 (1-100 µM) by sonication for 30 minutes at room temperature in a water bath 
sonicator (Branson), followed by heating at 56°C for 20 minutes, prior to addition to plates 
coated with CD1a. After 48 hours of incubation at room temperature, the plates were washed 
with PBS three times. T cells suspended in complete media were added to the plates (1-2x104 
skin CD4 T cells, or 1x105 lymph node CD4 T cells per well), and cultured for 3-5 days at 37°C 
in a CO2 incubator (Thermo Scientific). Culture supernatants were used for cytokine analysis by 
ELISA. 
 
Human T cell assays. For the psoriasis study, patients diagnosed with moderate-to-severe 
plaque psoriasis were included in the study based on their Psoriasis Area Severity Index (PASI). 
The PASI integrates criteria including erythema, induration, desquamation, and percentage of 
affected skin area. Monocyte-derived CD1a-expressing dendritic cells (mDCs) and memory CD4 
T cells were prepared as previously described10. mDCs were treated with LPS (100 ng/ml) for 3 
hours, prior to coculture with CD4 T cells. After expansion for 10 days, T cells were tested for 
CD1a auto-reactivity by co-culture with autologous mDCs at a ratio of 1:5 for 3 days in the 
presence of 10 µg/ml anti-CD1a or isotype control.  To test urushiol-specific T cell responses in 
humans, memory T cells isolated from peripheral blood mononuclear cells (PBMCs) of subjects 
who had poison ivy dermatitis in the last 6 months or control donors were expanded with 
autologous DCs pulsed with 2 µg/ml urushiol C15:2 for 10 days. Human IL-2 was added every 3 
days during cell culture. Subsequently, urushiol-specific T cell responses were determined by co-
culture of expanded T cells with urushiol C15:2- or vehicle-pulsed CD1a- or mock-transfected 
K562 cells at a ratio of 1:5. Three days after co-incubation, cells were used for intracellular 
cytokine staining and analyzed by flow cytometry, and culture supernatants were used for 
cytokine analysis by ELISA. K562 cells were routinely tested for mycoplasma contamination, 
and CD1a expression of transfectants was confirmed before use by flow cytometry. PBMCs were 
obtained from ConversantBio, ALLCELLS, and the Kraft Family Blood Donor Center at 
Brigham and Women’s Hospital. Informed consent was obtained from all subjects, and all 
human studies were approved by Boston Children’s Hospital’s Institutional Review Board (IRB). 
 
Flow cytometry and intracellular staining for cytokines. Cells were stained with antibodies 
against surface antigens in FACS buffer (PBS supplemented with 0.5% BSA) on ice for 30 
minutes. Subsequently, cells were washed and analyzed using a FACSCantoTM II flow cytometer 
(BD Biosciences). Propidium iodide or viability dye (eBioscience) was used to exclude dead 
cells. For intracellular cytokine staining, cells were stimulated ex vivo with 50 ng/ml phorbol 
myristate acetate (Sigma), and 5 µg/ml ionomycin (Sigma) in the presence of brefeldin A 
(BioLegend) in complete media for 4 hours at 37°C in a CO2 incubator. After surface staining, 
cells were fixed and permeabilized with BD Cytofix/Cytoperm solution followed by staining 
with antibodies against cytokines in Perm/Wash buffer (BD Biosciences). 
 
RNA extraction and real-time qPCR. Total RNA was purified from ear cells using the RNeasy 
Plus Mini Kit (Qiagen) according to the manufacturer's instructions. RNA was converted to 
cDNA with High Capacity RNA-to-cDNA Kit (Applied Biosystems). cDNA was mixed with 
primers and iTaq universal SYBR Green supermix (Bio-Rad), and relative expression was 
determined by real-time PCR using a 7300 Real-Time PCR System (Applied Biosystems). β-
actin was used as a housekeeping control. To calculate the relative fold change, the 2−ΔΔCT cycle 
threshold method was used. The following primer sequences were used:  
Actb, forward, 5’-TCCAGCCTTCCTTCTTGGGTATGGA-3’,  
Actb, reverse, 5’-CGCAGCTCAGTAACAGTCCGCC-3’, 
Il1b, forward, 5’-CAGGCAGGCAGTATCACTCA-3’, 
Il1b, reverse, 5’-AGGTGCTCATGTCCTCATCC-3’, 
Il22, forward, 5’-CCGAGGAGTCAGTGCTAAGG-3’,  
Il22, reverse, 5’-GTAGGGCTGGAACCTGTCTG-3’,  
Tnfa, forward, 5’-CCGATGGGTTGTACCTTGTC-3’, 
Tnfa, reverse, 5’-AGATAGCAAATCGGCTGACG-3’,  
Il23, forward, 5’-CCAGCGGGACATATGAATCT-3’,  
Il23, reverse, 5’-TGTGGGTCACAACCATCTTC-3’, 
Il10, forward, 5’-CCAAGCCTTATCGGAAATGA-3’, 
Il10, reverse, 5’-TCTCACCCAGGGAATTCAAA-3’, 
Il17A, forward, 5’-AGCTGGACCACCACATGAAT-3’, 
Il17A, reverse, 5’-AGCATCTTCTCGACCCTGAA-3’, 
Human Il22, forward, 5’-GCTTGACAAGTCCAACTTCCA-3’, 
Human Il22, reverse, 5’-GCTCACTCATACTGACTCCGT-3’, 
Human Il17A, forward, 5’-TCCCACGAAATCCAGGATGC-3’, 
Human Il17A, reverse, 5’-GGATGTTCAGGTTGACCATCAC-3’, 
Human Ifng, forward, 5’-TCGGTAACTGACTTGAATGTCCA-3’, 
Human Ifng, reverse, 5’-TCCTTTTTCGCTTCCCTGTTTT-3’. 
 Histology and confocal microscopy. Mice were euthanized by CO2 inhalation, and ear samples 
were frozen in Optimal Cutting Temperature (OCT) compound (Sakura Finetechnical 
Corporation). Ten µm-thick cross-sections were made and stained with hematoxylin and eosin by 
the Histology Core at Beth Israel Deaconess Medical Center. Images were taken using a BX63 
Motorized Microscope (Olympus). For epidermal sheets, ear pinnae were treated with shaving 
cream (SoftSheen-Carson) and affixed to slides with the epidermis downward. The ear samples 
were incubated in 10 mM EDTA in PBS for 2 hours at 37ºC, followed by physical removal of 
the dermis. Tissue was fixed in 4% paraformaldehyde (Sigma) at room temperature for 30 
minutes, and blocked with 10% FBS and 2% goat serum (Life Technologies) in PBS. Tissues 
were stained with purified anti-MHC class II and anti-CD1a, followed by staining with Alexa 
Fluor 647-conjugated anti-rat IgG, and Alexa Fluor 488-conjugated anti-mouse IgG as secondary 
antibodies. Samples were mounted with ProLong® Gold Antifade Mountant including DAPI 
(Life Technologies). Immunofluorescent images were taken using an Olympus FV1000 confocal 
microscope. 
 
Expression, purification of CD1a and urushiol (C15:2) loading into CD1a. The glycoprotein 
CD1a was expressed in a mammalian expression system and purified as previously described15. 
Following an endoglycosidase H (New England BioLabs) treatment, the purified CD1a was first 
loaded with the ganglioside GD3 (GD3) (Matreya LLC) that was dissolved in a solution 
containing 0.5% tyloxapol (Sigma) and 10 mM Tris buffer at pH 8.0. CD1a was first incubated 
with GD3 overnight at room temperature at a molar ratio of 1:15. The CD1a sample loaded with 
GD3 was further purified using ion exchange chromatography (MonoQ 10/100 GL-GE 
Healthcare). Urushiol C15:2 (Chemos) was dissolved in a solution containing 10 mM Tris buffer 
at pH 8.0 / 0.5% tyloxapol / 50% acetone (Sigma). The GD3–CD1a sample was then incubated 
overnight with urushiol at a 1:15 molar ratio and at room temperature in order to achieve the 
GD3 displacement by urushiol. A subsequent purification step involving ion exchange 
chromatography (MonoQ 10/100 GL) was performed to remove the excess of urushiol C15:2, 
GD3 –CD1a, and detergent.  
 
Crystallization, structure determination and refinement. Seeds obtained from previous 
binary CD1a-antigen crystals15 were used to grow crystals of the CD1a-urushiol (C15:2) binary 
complex in 20-25% PEG 1500 / 10% MMT buffer pH 5-6. The crystals were flash-frozen and 
data were collected at the MX2 beamline (Australian Synchrotron) to a 1.9Å resolution. All the 
data were processed with the program MOSFLM and were scaled with the CCP4 suite37. 
Consistent with the mass spectrometry data, the urushiol antigen was clearly evident in the 
unbiased electron density maps, in addition a trace amount of an endogenous self antigen was 
also evident on account of the high resolution of the binary complex. An initial run of rigid body 
refinement was performed with the refinement program BUSTER 2.1038. Iterative model 
improvement with COOT39 and further refinement with BUSTER 2.1038 were performed. The 
final refinement led to an R/R-free (%) of 18.6/21.6. The quality of the structure was confirmed 
at the Research Collaboratory for Structural Bioinformatics Protein Data Bank Data Validation 
and Deposition Services website. All presentations of molecular graphics were created with the 
PyMOL molecular visualization system (The PyMOL Molecular Graphics System, Version 
1.5.0.4 Schrödinger, LLC.). 
 
Extraction of urushiol and mass spectrometry analysis. In all samples, urushiol was extracted 
using a single phase Folch procedure40 and analyzed using a Q-Exactive Hybrid Quadrupole-
Orbitrap. Prior to urushiol extraction, crystals of CD1a-urushiol were extensively washed with 
the crystallization mother liquor and dissolved in Tris Buffer Saline (TBS), pH 8.0. MS coupled 
to a RSLC nano HPLC (Thermo Scientific, Bremen, Germany). Samples were loaded onto a 
nanoviper pepmap100 trap column (100μm x 2cm) in 2% acetonitrile / 0.1% ammonium acetate 
at a flow rate of 15 μL / minute. Analytes were separated at a flow rate of 300 μL / minute on a 
pepmap100 C18 column (75μm x 15cm, Thermo Scientific) using a linear gradient of 
acetonitrile (2-80%). Up to 12 MS/MS spectra were acquired per cycle with maximum 
accumulation time of 50 ms and 100 ms for MS1 and MS2, respectively. A SCIEX QTRAP 5500 
mass spectrometer was used for MRM-based detection as previously described41. The 5500 mass 
spectrometer was operated with unit quadrupole resolution and three MRM transitions were 
simultaneously monitored in detecting U15 315.2→149.1, 315.2→135.1, 315.2→122.1. Data 
analysis was performed using a combination of Analyst v1.5.2 and XCalibar 3.0 (Thermo Fisher 
Scientific).  
 
Statistical analysis. Data are presented as mean ± standard error. No statistical method was used 
to predetermine sample size, which instead was determined based on the results of preliminary 
experiments. Mice were allocated at random to experimental groups. Mouse studies were 
performed in a non-blinded fashion. To compare two groups, the two-tailed unpaired Student’s t-
test, or Mann-Whitney, or Wilcoxon test was used with or without the assumption of normality, 
respectively. The variance between groups was similar within each group. To compare more than 
two groups, one-way ANOVA test was performed with post multiple comparisons. p values > 
0.05 were considered not significant. All statistical analysis was calculated using Prism software 
(GraphPad).  
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Figure Legends 
Figure 1 CD1a facilitates Th17-mediated skin inflammation caused by poison ivy. Mice were 
sensitized by painting urushiol on the abdomen on day 0, and challenged with either urushiol or 
vehicle on the ear on day 5. (a) Ear swelling after challenge (n=5). * P<0.05, ** P<0.01, using 
Student’s t-test. (b) Cross-sections of ears obtained 2 days after challenge were stained with 
hematoxylin and eosin. E=Epidermis, D=Dermis, C=Cartilage; Scale bar: 100 µm. (c-h) Flow 
cytometry analysis of granulocytes and T cell subsets in ear skin 2 days after challenge. (c, d) 
Frequencies of inflammatory granulocytes (Gr-1highCD11bhigh) and macrophages (F4/80+Gr-1+, 
or F4/80+Gr-1-). (e) Frequencies of αβ and γδ T cells among live CD45+ cells. (f) Absolute cell 
numbers of indicated T cell subsets. (g, h) Frequencies and absolute cell numbers of IFN-γ+, IL-
17A+, and IL-22+ cells among TCRβ+CD4+ cells. Error bars represent s.e.m. Results are 
representative of 5 independent experiments. Three mice per group were used. * P<0.05, ** 
P<0.01; N.S., not significant, using Mann-Whitney test.  
 
Figure 2 Human subjects with poison ivy dermatitis show urushiol-specific T cell responses 
mediated by CD1a. Memory T cells were isolated from donors (n=6) who experienced contact 
dermatitis caused by poison ivy within the last 6 months, or healthy control donors (n=6), and 
cocultured with urushiol (C15:2)- or vehicle-loaded CD1a- or mock-transfected K562 cells for 3 
days. (a) Flow cytometry analysis of IL-17- and IL-22-producing CD4 T cells. (b) Frequencies 
of IL-22+ and IL-17A+IL-22+ cells among CD4 T cells. Error bars represent s.e.m. * P<0.05, ** 
P<0.01; N.S., not significant, using Mann-Whitney or Wilcoxon test. 
 
Figure 3 Urushiol-specific T cells are primed during the sensitization phase. Mice were 
challenged with urushiol on ear skin with or without prior sensitization. (a) Ear swelling 2 days 
after challenge. (b) Frequencies of Gr-1highCD11bhigh granulocytes (left), CD45+TCRβ+ cells 
among live cells (middle), and IL-17A+CD4+ cells among TCRβ+ cells (right). Error bars 
represent s.e.m. Results are representative of 3 independent experiments (n=3 per group for each 
experiment). ** P<0.01; N.S., not significant, using Student’s t-test. 
 
Figure 4 CD1a expression on Langerhans cells is essential for generation of Th17 cells and 
dermatitis. (a) Epidermal sheets were stained for MHC class II and CD1a, prior to analysis by 
confocal microscopy. Scale bar: 20 µm. (b) Cells were isolated from ears of naïve mice and 
stained for MHC-II, CD11c, CD1a, CD103, and CD207. Left plot presents CD1a expression on 
live CD11c+MHC-IIhi cells. Right plot shows CD103 and CD207 expression in CD1a-negative 
(I, green dots) and CD1a-positive (II, red dots) populations of CD1aTg mice gated from the left 
plot (3 independent experiments). (c) Langerhans cell (LC) population was analyzed 2 days after 
vehicle or urushiol challenge (n=3, 4 independent experiments). CD11c+MHC-IIintermediate (G1), 
CD103+CD207+ (G2a), and CD103-CD207+ (G2b) cells among CD11c+MHC-IIhi (G2) cells of 
urushiol-challenged mice were further analyzed for CD1a expression (far right). (d-g) Wild-type, 
CD1aTg, or CD1aTg mice injected with either isotype or anti-CD1a antibody were sensitized 
and challenged with urushiol (n=3, 4 independent experiments). (d) Ear swelling on day 2. Ears 
and draining lymph nodes (dLN) were harvested and analyzed by flow cytometry for (e) 
frequencies of inflammatory Gr-1hiCD11bhi granulocytes (top), and IL-17A+ or IFN-γ+ cells 
among CD45+TCRβ+CD4+cells (bottom), (f) absolute cell numbers of CD4+ T cells (top), and 
IL-17A-producing CD4+ T cells (bottom), and (g) CD1a expression on LCs in ear skin and dLN. 
Error bars represent s.e.m. * P <0.05, ** P <0.01; N.S., not significant, using one-way ANOVA 
and multiple comparisons.  
 
Figure 5 Urushiol is an antigen for CD1a-restricted T cells. (a, b) Skin CD4+ T cells were 
isolated on day 2 after urushiol challenge, and (a) stimulated by plate-bound CD1a loaded with 
50 µM natural urushiol (n=3, 5 independent experiments), or (b) various concentrations (10, 50, 
100 µM) of synthetic urushiol C15:0, C15:1, C15:2, or C15:3 for 5 days. Concentrations of IL-
17A in supernatants were measured by ELISA (n=3, 3 independent experiments). (c, d) Mice 
were immunized with urushiol C15:2. (c) Ear swelling in wild-type and CD1aTg mice on day 2 
after challenge (4-7 mice per group, 4 independent experiments). (d) Skin LCs were pulsed with 
C15:2 urushiol, and co-cultured with dLN CD4+ T cells for 3 days in the presence or absence of 
anti-CD1a antibody. Concentrations of IL-17A in supernatants were measured by ELISA (n=3, 2 
independent experiments, N.D., not detectable). Error bars represent s.e.m. * P<0.05, ** P<0.01; 
N.S., not significant, using Student’s t-test.  
Figure 6 CD1a binds and displays urushiol (C15:2) in its antigen-binding cleft. (a) Molecular 
interactions of urushiol (C15:2) with CD1a. Superposition of the CD1a-urushiol binary complex 
(in grey) and the complex of TCR-CD1a-endogenous lipid (in light blue) (PDB code: 4X6D). (b) 
Extracted ion chromatograms (Q1-Q3 transition) of urushiol C15:2 synthetic standard (in black), 
purified recombinant CD1a loaded with urushiol (in green), and crystal of CD1a-urushiol C15:2 
(in red). (c) Accurate mass spectra for urushiol extracts comparing predicted molecular weight 
and isotope distribution pattern. (i) urushiol C15:2 theoretical mass, (ii) urushiol C15:2 synthetic 
standard, (iii) purified CD1a-urushiol C15:2 soluble extract, and (iv) CD1a-urushiol C15:2 
binary complex crystal.  
 
Figure 7 CD1a is a novel target for treatment of psoriatic inflammation. (a, b) Imiquimod (IMQ) 
was applied on ears of wild-type and CD1aTg mice for 6 days. (a) Representative hematoxylin 
and eosin stainings of tissue sections, and photographs of ears on day 7. Black arrows indicate 
epidermal thickening. Scale bar: 100 µm. (b) Ear swelling on day 7 (n=5, 5 independent 
experiments), *** P <0.001, using Student’s t-test. (c-e) IMQ was applied on ears of wild-type, 
CD1aTg, and CD1aTg mice injected with either isotype or anti-CD1a antibody for 6 days.  (c) 
Ear swelling (n=6-8 per group), (d) frequencies of Gr-1highCD11bhigh granulocytes and TCR-
β+CD4+ cells among live CD45+ cells, and (e) absolute cell numbers of IL-17A-, IL-17F-, and 
IL-22-producing CD4+ T cells isolated from challenged ears (n=3 per group, 3 independent 
experiments). (f) dLN CD4+ T cells of wild-type and CD1aTg mice treated or non-treated with 
IMQ for 6 days were stimulated by plate-bound CD1a loaded with fatty acid (FA), squalene 
(SQ), wax ester (WE), or triacylglycerol (TAG) for 5 days. Concentrations of IL-17A in 
supernatants were measured by ELISA (n=3, 3 independent experiments). (g) Memory T cells 
were isolated from patients with active psoriasis (n=6), or healthy donors (n=6), and cocultured 
with autologous monocyte-derived DCs in the presence or absence of anti-CD1a or isotype for 3 
days. Concentrations of IL-17A and IL-22 in supernatants were determined by ELISA. Error 
bars represent s.e.m. * P <0.05, ** P <0.01, *** p<0.001, **** p<0.0001, using one-way 
ANOVA and multiple comparisons.   
 
 
 
 Supplementary Figure 1 Cytokine pattern in skin in response to urushiol. Mice were sensitized 
and challenged with urushiol. Quantitative real-time PCR was performed to analyze cytokine 
gene expression in the ear tissue obtained 2 days after challenge. Results are presented as fold 
increases over vehicle-treated ears from wild-type mice. Error bars represent s.e.m., n=3. Results 
are representative of 2 independent experiments.  
 
Supplementary Figure 2 CD1a suppresses contact hypersensitivity mediated by IFN-γ-
producing cells. Mice were sensitized with 0.5% DNFB by painting on the abdomen on day 0, 
and challenged with either 0.2% DNFB or vehicle on ears 5 days after sensitization. (a) Ear 
swelling after challenge. (b) Frequencies of Gr-1highCD11bhigh granulocytes (left), CD4+ and 
CD8+ T cells among live CD45+TCRβ+ cells (middle), and IL-17A+ or IFN-γ+ cells among 
TCRβ+ cells (right). (c) Absolute cell numbers of CD8 or CD4 αβT cells, IFN-γ- or IL-17A-
producing cells in ears. Error bars represent s.e.m. Results are representative of 3 independent 
experiments (n=3 per group for each experiment). ** P<0.01, *** P<0.001, using Student’s t-
test. 
 
Supplementary Figure 3 Vβ TCR subfamily profile in skin and thymus. (a-e) Ear cells or 
thymocytes were isolated from wild-type or CD1aTg mice 2 days after urushiol C15:2 or vehicle 
challenge and analyzed for 15 different Vβ TCR subfamilies. Relative contribution of each Vβ+ 
cell subset among CD45+CD3+CD4+ T cells is presented in bar graphs. (a) Vβ TCR repertoire in 
urushiol-treated skin. (b) Frequencies of IL-17A+ cells among Vβ2+ or Vβ4+ CD4+ T cells in ear. 
Error bars represent s.e.m. (c) Frequencies of Vβ2+ or Vβ4+ cells in ears from CD1aTg versus 
CD1aTg mice injected with anti-CD1a antibody. (d) Vβ TCR repertoire in vehicle-treated skin.  
Error bars represent s.e.m. (e) Vβ TCR repertoire in thymus. Results are representative of 2-3 
independent experiments. * P<0.05, ** P<0.01; N.S., not significant, using Mann-Whitney test.  
 
Supplementary Figure 4 Crystal structure of the CD1a-urushiol complex. (a) Overall cartoon 
representation of the binary crystal structure of CD1a-urushiol C15:2. (b) Top view of the 
molecular surface of the α1- and α2- domains of CD1a (in grey) and the bound urushiol shown 
as spheres (in magenta). (c) Fo-Fc electron density map (yellow orange) of urushiol contoured at 
2.2 σ level. (d) 2Fo-Fc electron density map (in blue) of urushiol contoured at 0.8 σ level.  
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Supplementary Table 1 Data collection and refinement statistics 
 
 CD1a-Urushiol 
 
Data collection   
Temperature 100K 
Resolution limits (Å) 45.8-1.86 (1.9-1.86) 
Space Group P212121 
Cell dimensions (Å)  a=42.2, b=90.3, 
c=106.2 α=β=γ=90.00°  
 
Total No.  observations 506717 (31388) 
No.  unique 
observations 
35008 (2139) 
Multiplicity 14.5 (14.7) 
Data completeness 100 (100) 
Wilson B-factors (Å2) 22.9 
I/σ1 15.5 (3.7) 
Rp.i.m 
1 (%) 3.8 (36) 
  
Refinement statistics  
Rfactor 
2 (%) 18.6 
Rfree 
3 (%) 21.6 
Non hydrogen atoms 
- Protein 
- Water 
- Heterogen 
 
2927 
250 
23 
Ramachandran plot 
(%)  
- Most favoured 
- Allowed 
 
 
97.55 
2.17 
B-factors (Å2) 
- Average main 
chain  
- Average side 
chain 
- Urushiol 
 
29.3 
 
35.4 
 
55.3 
rmsd bonds (Å) 0.010 
rmsd angles (°) 1.00 
 
1 Rp.i.m = Σhkl [1/(N-1)]1/2  Σi | Ihkl, i - <Ihkl> | / Σhkl <Ihkl> 
2 Rfactor = ( Σ | |Fo| - |Fc| | ) / ( Σ |Fo| )  - for all data except as indicated in footnote 3. 
3 5% of data was used for the Rfree calculation  
Values in parentheses refer to the highest resolution bin. 
 
 
 
Supplementary Table 2 CD1a contacts with Urushiol 
 
CD1a residues Urushiol atoms Bond type 
Val12 C1, C2, C3, C6’ VDW 
Trp14 C8, C9 VDW 
Leu66 C3’, O3’ VDW 
Leu66-O O3’ HB 
Phe70 C1, C1’, C2’, C3’, O2’, O3’ VDW 
Arg76 C15 VDW 
Ser 77 C8, C9, C10, C13, C14, C15 VDW 
Gly80 C15 VDW 
Ile81 C12 VDW 
Val98 C5 VDW 
Leu116 C11 VDW 
Phe144 C12 VDW 
Leu148 C12, C13, C14 VDW 
 
HB: Hydrogen bond, VDW: Van der Waals, SB: salt bridge. Cut-off at 4 Å for VDW 
interactions and 3.5 Å for HB. 
 
